Relay Therapeutics Inc (RLAY)
NASDAQ:RLAY
Want to see RLAY full AI Analyst Report?
RLAY Stock Chart & Stats
$16.76
>-$0.01(-0.22%)
At close: 4:00 PM EST
$16.76
>-$0.01(-0.22%)
Day’s Range― - ―
52-Week Range$3.03 - $17.47
Previous CloseN/A
Volume391.09K
Average Volume (3M)4.47M
Market Cap
$3.46B
Enterprise Value$2.55B
Total Cash (Recent Filing)$642.07M
Total Debt (Recent Filing)$31.57M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Aug 06, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding217,940,340
10 Day Avg. Volume3,615,534
30 Day Avg. Volume4,471,876
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.56
Price to Sales (P/S)94.54
P/FCF Ratio-6.15
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue238.85
Enterprise Value/Gross Profit-43.73
Enterprise Value/Ebitda-9.33
Forecast
1Y Price Target
$23.56Price Target Upside40.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.57
Revenue Forecast (FY)$11.88M
Bulls Say, Bears Say
Bulls Say
Proprietary Computational Discovery PlatformRelay's platform emphasizing protein motion and structure-based discovery is a durable competitive advantage: it can raise hit-to-lead efficiency, accelerate candidate selection across indications, and attract partnerships. That foundational tech supports sustained pipeline productivity and differentiation over multiple development cycles.
Promising Phase 2 Zovegalisib Data In Rare DiseaseRobust early efficacy and manageable chronic-dose safety in PIK3CA-driven vascular anomalies materially de-risks a non-oncology revenue path. Successful rare-disease positioning can enable accelerated regulatory pathways, durable market niches, and diversified future revenue beyond oncology if later trials confirm these signals.
Bolstered Liquidity From Recent Equity OfferingA sizable ~$297M equity raise materially extends runway for long-cycle R&D and planned Phase 3 moves. Coupled with low leverage, this funding reduces near-term financing pressure, supports execution of pivotal trials, and preserves capacity to advance multiple programs before needing additional capital.
Bears Say
High, Persistent Cash BurnSustained negative operating and free cash flow means Relay remains dependent on external financing or milestone payments. Over the medium term this creates recurring dilution risk, constrains discretionary investment, and requires careful capital allocation to prevent disruption of pivotal trials or program timelines.
Deep, Sustained Operating Losses And Erosion Of EquityLarge recurring losses erode shareholders' capital and reduce financial flexibility. Negative returns and declining equity signal that profitability is distant, increasing reliance on dilution or partnerships and limiting ability to self-fund expansions or launch commercialization without substantive external support.
Small, Volatile, Partnership-dependent RevenueReliance on collaboration payments and milestone timing creates uneven cash inflows and uncertain long-term revenue visibility. Without commercial products, durable revenue growth depends on successful late-stage outcomes or new deals, making sustained self-funded operations vulnerable to clinical or partner delays.
Relay Therapeutics News
RLAY FAQ
What was Relay Therapeutics Inc’s price range in the past 12 months?
Relay Therapeutics Inc lowest stock price was $3.02 and its highest was $17.47 in the past 12 months.
What is Relay Therapeutics Inc’s market cap?
Relay Therapeutics Inc’s market cap is $3.46B.
When is Relay Therapeutics Inc’s upcoming earnings report date?
Relay Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 45 days.
How were Relay Therapeutics Inc’s earnings last quarter?
Relay Therapeutics Inc released its earnings results on May 05, 2026. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.363 by -$0.047.
Is Relay Therapeutics Inc overvalued?
According to Wall Street analysts Relay Therapeutics Inc’s price is currently Undervalued.
Does Relay Therapeutics Inc pay dividends?
Relay Therapeutics Inc does not currently pay dividends.
What is Relay Therapeutics Inc’s EPS estimate?
Relay Therapeutics Inc’s EPS estimate is -0.39.
How many shares outstanding does Relay Therapeutics Inc have?
Relay Therapeutics Inc has 217,940,340 shares outstanding.
What happened to Relay Therapeutics Inc’s price movement after its last earnings report?
Relay Therapeutics Inc reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.363. Following the earnings report the stock price went down -0.615%.
Which hedge fund is a major shareholder of Relay Therapeutics Inc?
Currently, no hedge funds are holding shares in RLAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relay Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.56 (40.55% Upside)
$23.56 (40.55% Upside)
Blogger Sentiment
Bullish
RLAY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 7.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $47.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 10.1%
Last 30 Days ▲ 10.1%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
372.61%
12-Months-Change
Fundamentals
Return on Equity
-43.94%
Trailing 12-Months
Asset Growth
-12.48%
Trailing 12-Months
Company Description
Relay Therapeutics Inc
Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
RLAY Stock 12 Month Forecast
Average Price Target
$23.56
▲(40.55% Upside)
Technical Analysis
Ownership Overview
1.87% Insiders
8.24% Mutual Funds
52.14% Other Institutional Investors
25.91% Public Companies and Individual Investors